It is demonstrated that Cu MOF/R848 integrates photothermal ablation with immune activation, providing a promising nanoplatform for HCC therapy.
Abstract
Hepatocellular carcinoma (HCC), the most common type of liver cancer, remains a major cause of cancer-related mortality worldwide, with limited treatment options and poor prognosis in advanced stages. Immunotherapy has shown promise in treating advanced HCC, with the TLR7/8 agonist resiquimod (R848) effectively activating both innate and adaptive immunity. However, its clinical application is limited by poor solubility, rapid clearance, toxicity, and the inherently low immunogenicity of HCC. To enhance therapeutic efficacy, combination strategies are increasingly explored. Here, we developed a multifunctional copper-based metal–organic framework (Cu MOF) nanoparticles encapsulating R848 (Cu MOF/R848) for synergistic photoimmunotherapy against HCC. Cu MOF/R848 achieves efficient pH-responsive release in the tumor microenvironment. Photothermal therapy (PTT) utilizes the light-absorbing properties of Cu MOF to convert near-infrared (NIR) light into heat, thereby disrupting mitochondria, inducing tumor cell apoptosis, and promoting immunogenic cell death (ICD). This photothermal effect facilitates the release of tumor-associated antigens, while R848 acts as an immune stimulant, together eliciting a robust systemic antitumor response. In vitro, Cu MOF/R848 combined with NIR irradiation induced apoptosis in hepatoma cells by modulating pro- and anti-apoptotic proteins, including upregulating Bax and downregulating Bcl-2, thereby effectively inhibiting cell proliferation and promoting dendritic cell maturation. In vivo, the treatment achieved effective tumor ablation, suppressed neovascularization, and enhanced systemic immune responses by activating CD8+ and CD4+ T cells, promoting their infiltration into tumor tissues, and elevating serum levels of TNF-α and IFN-γ. Collectively, these findings demonstrate that Cu MOF/R848 integrates photothermal ablation with immune activation, providing a promising nanoplatform for HCC therapy.
Emerging copper-mediated lethal mechanisms provide cancer therapies, with current research emphasizing precise copper regulation to enhance its dual role in tumor pathology. Here, we presented a bimetallic nanoplatform, HMCuS/Ru/ICG/GOx@9R-P201Ti (HRIG9R), designed to amplify cuproptosis for hepatocellular carcinom...
Wen-Qi Zhu, Lin-Song Li, Bang-Bang Liu et al.· Nano Reseach· 0 citations
Cu2-xSe has made many breakthroughs in tumor therapy due to its unique advantages. Cu2-xSe can enhance immunotherapy by multiple mechanisms, such as reshaping the immunosuppressive tumor microenvironment (TME) and triggering immunogenic cell death. Cu2-xSe possesses a variety of nanozyme-like activities that can disrup...
Jing-Chao He, Jia-Chao Xie, Yun-Xiao Peng et al.· Frontiers in Chemistry· 0 citations
Its pH-responsive drug delivery and combined antitumor effects suggest that ZIF-8-based nanocarriers may provide a promising strategy for precision cancer therapy.
Long Zhang, Wei-Jie Zhu, Lei He et al.· International Journal of Gen...· 0 citations
In vivo animal studies demonstrate that the synergistic combination of TMP's PDT activity and CpG's immunotherapeutic effects significantly suppresses tumor growth, and represents a promising adjuvant chemotherapy strategy capable of boosting immune activation and therapeutic outcomes against drug-resistant tumors.
Xin-Hui Zhai, Yifan Liu, Yazixuan Feng et al.· Journal of materials chemist...· 0 citations
Cancer is a leading cause of death. Melanoma, a highly metastatic and aggressive skin cancer, has seen rising mortality rates despite advancements in chemotherapy. Recently, immunotherapy has emerged as a promising approach to address the limitations of conventional treatments. This study developed a tumor microenviron...
Photothermal therapy (PTT) offers the advantages of noninvasiveness and high selectivity, while chemotherapy shows potent antitumor activity. However, their standalone applications are limited by insufficient photothermal ablation efficacy and chemotherapeutic resistance, respectively. To address these challenges, we d...
Yu Jiang, Chen Guo, Zhen-Kun Sun et al.· Molecular Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.